Sharon R. Klein (CIPP/US), a partner with Pepper Hamilton, chair of the firm's Privacy, Security and Data Protection practice and a leader of the Technology practice, was quoted in the December 29, 2017 Bloomberg BNA Health Care Blog post, "Today’s Trust in Tech May Make New Tracking Pill Digestible."
With widespread adoption of fitness trackers like Fitbit and genetic testing providers like 23andMe, the public may be comfortable with “digital drugs” such as Abilify MyCite, Pepper Hamilton LLP’s Sharon Klein told Bloomberg Law for a story on the newly approved product.
“I think it’s trending that way,” she said. “People are wanting more information.”
“This is just a natural extension of precision medicine,” Klein said, referring to the use of person-specific data (such a patient’s genetic makeup and lifestyle) to prevent and treat disease. “You’re trying to get to the person, and what better way to get to the person than having something ingested, whether it’s a sensor or an embedded microchip?”